Progress of Auto-HSCT for Treatment of DLBCL--Review.
10.7534/j.issn.1009-2137.2018.06.044
- Author:
Xi WANG
1
;
Bing XIA
1
;
Yi-Zhuo ZHANG
2
Author Information
1. Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Tianjin Municipal Key Laboratory of Cancer Prevention and Therapy，Tianjin Municipal Clinical Research Center for Cancer，Tianjin 300060，China.
2. Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Tianjin Municipal Key Laboratory of Cancer Prevention and Therapy，Tianjin Municipal Clinical Research Center for Cancer，Tianjin 300060，China E-mail:18622221239@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, Large B-Cell, Diffuse;
therapy;
Transplantation Conditioning;
Transplantation, Autologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2018;26(6):1841-1846
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B cell lymphoma（DLBCL）is the most common non-Hodgkin's lymphoma in adults，accounting for 30%-40% of non-Hodgkin's lymphoma in adults. The treatments of this lymphoma mainly include chemotherapy，radiotherapy and autologous hematopoietic stem cell transplantation. A large amount of studies show that autologous hematopoietic stem cell transplantation considered as the main treatmant approach can be used for primary high-risk young and relapsed or refractory DLBCL patients. Many scholars have evaluated the effectiveness of autologous hematopoietic stem cell transplantation for primarily high-risk young and relapsed or refractory DLBCL patients，and tried to improve the effectiveness of transplantation that showed some advantagcs for DLBCL patients.
